AVX701

AXP000213.1 · Cancer vaccine

Platform
alphavirus (VEE) virus-like replicon particles
Targets
CEACAM5
Originator
AlphaVax
Sponsor
AlphaVax / Duke University

Names

NameTypeSource
AVX701preferred name, codecurator, ncit
CEA(6D) VRPsynonymncit

Virus

Role
Vaccine vector
Family
Togaviridae
Virus
Venezuelan equine encephalitis virus (NCBI Taxonomy 11036)
Strain
VEE replicon, packaged as virus-like replicon particles
Replication
non replicating
Modifications
structural protein genes replaced by the transgene so the replicon cannot be amplified further in the recipient; particles packaged with structural proteins supplied in trans
Transgenes
CEACAM5 (CEA(6D))
Route
intramuscular
Source
evidence

Cross-references

NCI Thesaurus
C70644

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT01890213Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal CancerCompletedPhase 12013-112017-0612Stage III Colon Cancer
NCT00529984A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing MalignanciesCompletedPhase 1/22007-092010-0528Breast Cancer; Colon Cancer; Colorectal Cancer; Lung Cancer; Pancreatic Cancer

Recent changes

No changes recorded in its trials yet.

Notes

Propagation-defective Venezuelan equine encephalitis virus replicon packaged as virus-like replicon particles encoding CEA(6D); intramuscular. Phase 1/2 in advanced CEA-expressing cancer (NCT00529984, PMID 20679728). Included as a cancer vaccine, which this pass admits at any phase.

How to cite

AVX701 (AXP000213.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000213.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.